Lineage Cell Therapeutics Inc. (LCTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lineage Cell Therapeutics... (LCTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.55

-0.05 (-8.15%)

At close: Jan 14, 2025, 3:59 PM

0.55

-0.31%

After-hours Jan 14, 2025, 08:00 PM EST

undefined% (undefined)

Bid	0.54
Market Cap	121.60M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.1
PE Ratio (ttm)	-5.52
Forward PE	n/a
Analyst	Buy

Ask	0.57
Volume	1,231,876
Avg. Volume (20D)	2,294,996
Open	0.59
Previous Close	0.60
Day's Range	0.54 - 0.59
52-Week Range	0.48 - 1.61
Beta	undefined

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 5, 1992

Employees 68

Stock Exchange AMEX

Ticker Symbol LCTX

Website https://www.lineagecell.com

Analyst Forecast

According to 5 analyst ratings, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 625.03% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Lineage Cell Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $1.62M, reflecting a -22.86% YoY shrinking and earnings per share of -0.03, making a 0.00% YoY.

Why Price Moved

1 month ago · Source

-28.99%

Lineage Cell Therapeutics shares are trading lower... Unlock content with Pro Subscription

5 months ago · Source

+1.8%

Lineage Cell Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

News

4 weeks ago · zacks.com

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys...

1 month ago · businesswire.com

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell ...

1 month ago · zacks.com

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima...

2 months ago · seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.